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Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic
tool to standardize interpretation
Aims: Accurate determination of HER-2 status is crit-
ical to identify patients for whom trastuzumab treat-
ment will be of beneﬁt. Although the recommended
primary method of evaluation is immunohistochemis-
try, numerous reports of variability in interpretation
have raised uncertainty about the reliability of results.
Recent guidelines have suggested that image analysis
could be an effective tool for achieving consistent
interpretation, and this study aimed to assess whether
this technology has potential as a diagnostic support
tool.
Methods and results: Across a cohort of 275 cases,
image analysis could accurately classify HER-2 status,
with 91% agreement between computer-aided classi-
ﬁcation and the pathology review. Assessment of
the continuity of membranous immunoreactivity in
addition to intensity of reactivity was critical to
distinguish between negative and equivocal cases and
enabled image analysis to report a lower referral rate of
cases for conﬁrmatory ﬂuorescence in situ hybridization
(FISH) testing. An excellent concordance rate of 95%
was observed between FISH and the automated review
across 136 informative cases.
Conclusions: This study has validated that image
analysis can robustly and accurately evaluate HER-
2 status in immunohistochemically stained tissue.
Based on these ﬁndings, image analysis has great
potential as a diagnostic support tool for pathologists
and biomedical scientists, and may signiﬁcantly
improve the standardization of HER-2 testing by
providing a quantitative reference method for inter-
pretation.
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Targeted therapeutics or personalized medicine regimes
are driving a new era of integrated diagnostics and
therapeutics, particularly in oncology. Many antican-
cer antibodies have been approved in association with
companion tests for biomarker expression to identify
the most responsive patients, ensuring that accurate
evaluation of biomarker status has become particularly
acute in the clinical laboratory. The role that biomar-
kers can play is exempliﬁed by HER-2: a prognostic,
predictive and therapy selection factor for patients with
breast cancer. Ampliﬁcation of the HER-2 gene or
overexpression of its protein product in cell membranes
is seen in 10–30% of invasive breast cancer and is
associated with increased disease recurrence and poor
prognosis.
1–5 Clinically, HER-2 is important as the
target of the monoclonal antibody trastuzumab (Her-
ceptin
 , Genentech, CA, USA), which signiﬁcantly
improves response rate, disease progression and overall
survival when used in an adjuvant setting compared
with chemotherapy alone.
6–8 The association between
HER-2 expression and Herceptin
  response has led to
the recommendation that this parameter should be
evaluated in every primary invasive breast cancer to
distinguish those patients for whom the drug may be of
beneﬁt, not only because of the expense of treatment,
but also because of its potential to cause myocardial
toxicity if incorrectly prescribed.
9–11
The therapeutic relevance of HER-2 status demands
highly reliable and robust testing to identify tumours
that overexpress this protein.
12 The recommended
evaluation method for HER-2 is immunohistochemistry
(IHC) to detect expression of the HER-2 protein in cell
membranes, with equivocal cases conﬁrmed at the
gene expression level using ﬂuorescence in situ hybridi-
zation (FISH).
9,11 FISH is considered the gold-standard
method of evaluation, affording an objective and
quantitative scoring system; however, this technique
suffers from fading ﬂuorochromes and thus poor long-
term stability, in addition to a requirement for special-
ized microscopic equipment that restricts its use in
conventional laboratories.
8,12 Chromogenic in situ
hybridization (CISH) or silver-enhanced in situ hybrid-
ization, which do not rely on ﬂuorescent microscopy,
represent alternatives to FISH in terms of HER-2
oncogene analysis. However, although these methods
have been determined to give comparable results to
FISH, they are not yet widely utilized in diagnostic
pathology.
11,13
In contrast, qualitative IHC testing is advocated as
the primary assay for identifying candidates for trast-
uzumab because it is readily available, easily performed
in most clinical pathology laboratories and has many
advantages over FISH or CISH in terms of economics,
as well as being highly amenable to automa-
tion.
8,10,14,15 Nonetheless, despite efforts to standardize
assay protocol and interpretation, antibodies and
methods vary across laboratories and IHC scoring
remains an inherently subjective process to which only
limited statistical conﬁdence can be assigned due to
inherent observer variability and the semiquantitative
nature of the data.
8,10,16–19 Even for the trained eye of
a pathologist, accurate distinction between the nomi-
nal categories (0, 1+, 2+, 3+) is difﬁcult and often
arbitrary, and signiﬁcant variation is introduced as a
result of overusing the intermediate category during
reviews.
2,20
Recently, high rates of discordance between IHC
reviewed at high-volume HER-2 reference centres and
low-volume regional laboratories has cast doubt on the
reliability of results.
5,21–23 As this stands alone in
determining which patients are likely to respond to
trastuzumab therapy, additional attention to the per-
formance and interpretation of IHC testing is now
warranted.
24,25 Participation in external quality assur-
ance (EQA) schemes is recommended and, according to
the updated National Comprehensive Cancer Network
guidelines, if standards cannot be met material should
be sent to a reference laboratory. Nonetheless,
although the current EQA schemes assess methodolo-
gies, they do not attend to disparity in interpretation; in
order to address this the American Society of Clinical
Oncology has suggested that image analysis could be
an effective tool for achieving consistency.
9 Indeed,
virtual pathology, the process of assessing digital
images of histology slides, is gaining momentum in
today’s laboratory environment, with digital image
acquisition systems commonplace and associated im-
age analysis solutions viewed by most as the next
critical step.
26 Image analysis may serve to reduce
scoring variability by providing a quantitative HER-2
reference tool, thus standardizing the evaluation
system.
Thus there is an urgent need to develop more
sensitive image analysis tools that may be utilized with
any of the prevalent HER-2 antibody kits in clinical
pathology. Towards this goal, we have developed a
HER-2 image analysis algorithm that may be applied to
slides immunohistochemically stained with Dako Her-
cepTest
  (Dako, Glostrup, Denmark), Ventana Path-
way
  (Ventana, Tucson, AZ, USA) or Leica Oracle
TM
(Leica, Heerbrugg, Switzerland) HER-2 antibodies. In
particular our approach employs a novel quantiﬁcation
base, determining the continuity or extent of circum-
ferential membranous immunoreactivity, a parameter
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important factor for differentiating HER-2 classiﬁcation.
It is hypothesized that by considering this parameter,
the number of ambiguous cases may be reduced by
enabling better separation between negative and
equivocal groups. This multi-site study set out to assess
whether this HER-2 algorithm could improve the
diagnostic accuracy of IHC scoring, with the perfor-
mance of the algorithm measured against both manual
review and FISH evaluation as the accepted standard.
Materials and methods
slide preparations
A total of 448 consecutive cases were selected for this
study from the archives of Beaumont Hospital and
Adelaide and Meath Hospital, two HER-2 reference
laboratories in Dublin, Ireland, of which 425 were
successfully stained, reviewed and digitized. All cases
were formalin ﬁxed, parafﬁn embedded and processed
in the routine diagnostic laboratory of the institute of
origin according to standardized protocols.
Immunohistochemistry
The cases supplied from Beaumont Hospital were
assessed for HER-2 protein expression using Dako
HercepTest
  (n = 144) and Leica Oracle
TM HER-2
(n = 140) antibodies according to the manufacturer’s
instructions. Those cases supplied from Adelaide and
Meath Hospital were analysed for HER-2 protein
expression with Ventana Pathway
  HER-2 (4b5)
(n = 141) according to the manufacturer’s instruc-
tions. In all cases, suitable negative and positive control
slides were treated in a similar manner to ensure
appropriate staining.
Fluorescence in situ hybridization
A representative cohort of cases was selected for FISH
testing for veriﬁcation purposes. Of the 425 cases
supplied, 219 were analysed for HER-2 gene ampliﬁ-
cation using the PathVysion
  HER-2 DNA probe kit
and parafﬁn wax pretreatment kit (Vysis Inc., Queen-
borough, UK) in the facility of origin. All procedures
were performed in accordance with the manufacturer’s
recommended protocol.
Digitization of slides and archival of images
Immunohistochemically stained full-face sections were
digitized by SlidePath using a NanoZoomer Digital
Pathology (NDP) System (Hamamatsu, Welwyn Gar-
den City, UK). The NDP system utilizes charge-coupled
device time delay integration technology to achieve
scans with a spatial resolution of 0.46 lm ⁄ pixel.
Scanning time at 20· was approximately 3 min for a
20 · 20 mm biopsy specimen. Images were approxi-
mately 55–487 Mb per whole section biopsy specimen
and were archived using SlidePath’s Digital Slideserver,
a secure, web-enabled digital slide management
system.
manual evaluation of her-2 status
At each site, HER-2 protein expression was reviewed by
a Consultant Pathologist. For those cases where FISH
analysis was carried out, gene ampliﬁcation status was
reviewed by a Biomedical Scientist. All cases were
classiﬁed according to the new American Society of
Clinical Oncology ⁄ College of American Pathologists
(ASCO ⁄ CAP) and UK guideline recommendations for
HER-2 testing as detailed in Table 1.
image analysis classification of her-2 status
Tissue IA system
The HER-2 image analysis algorithm was deployed
within SlidePath’s Tissue IA system, a web-enabled
image analysis solution for the interpretation of virtual
slides. As a prerequisite for image analysis, invasive
tumour regions of all cases were annotated on-line by
Table 1. American Society of Clinical Oncology ⁄ College of American Pathologists and UK guideline recommendations for
HER-2 classiﬁcation
9,11
Classiﬁcation
HER-2
grade IHC staining pattern FISH criteria
Negative 0 ⁄ 1+ No staining or weak, incomplete membranous staining in
<10% of tumour cells
HER2 ⁄ Chr17
ratio <1.8
Equivocal 2+ Weak to moderate complete membranous staining that is
non-uniform or weak in intensity in at least 10% of cells
HER2 ⁄ Chr17 ratio
between 1.8 and 2.2
Positive 3+ Uniform, intense membranous staining in >30% of tumour
cells
HER2 ⁄ Chr17 ratio >2.2
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sive or ductal carcinoma in situ regions excluded from
analysis (Figure 1).
Entire full-face sections or annotated regions of these
cases were subsequently submitted for batch image
analysis. Tissue IA employs a grid computing model
that distributes image data across multiple processing
nodes, facilitating high-throughput automated analysis
of virtual slides. The HER-2 algorithm utilizes a speciﬁc
colour deﬁnition ﬁle to deﬁne immunopositive tissue
within an image and isolates the cell membrane using
edge detection techniques. The output from the algo-
rithm includes a number of quantitative measurements
such as membrane staining absorbance, percent mem-
brane positive pixels in tissue and percent membrane
continuity.
Generation of probability classiﬁer
From the total cohort of 425 cases, a training set of
150 cases containing an equal distribution of slides
stained with Ventana Pathway
 , Leica Oracle
TM and
Dako HercepTest
  antibodies was randomly chosen by
assigning cases with a random real number ‡0 and <1
and selecting the 50 highest numbers for each antibody
cohort. Table 2 illustrates the distribution of cases
according to the manual review in the training and
validation sets.
The image analysis results for these slides were
exported for statistical analysis and were used to
generate a probability classiﬁer, which determined a
dedicated HER-2 score (0 ⁄ 1+, 2+ or 3+) based on the
distribution of staining absorbance and membrane
continuity for each category. In addition, a constraint
was included that automatically deﬁned any case with
<1% immunopositive pixels in selected regions as
negative or 0 ⁄ 1+. These computational steps were
then incorporated into the algorithm, resulting in an
output of a dedicated HER-2 classiﬁcation, along with a
percentage conﬁdence in that score.
Validation of cell-line standards
For 180 of the 275 remaining test cases the manufac-
turer control cell line material was also available for
analysis. Cell lines provide consistency in terms of both
the quantity of material and the gradation of protein
expression, and when used as part of a validated system
have applications in internal quality assurance, pro-
viding a standard against which a laboratory can
gauge against day-to-day drift in assay sensitivity.
Figure 1. As a prerequisite for
image analysis and in accor-
dance with clinical guidelines,
the non-invasive regions of
tumour were annotated online
by a Pathologist and excluded
from analysis.
Table 2. Distribution of cases in training and validation sets
Training set Validation set
Number
of cases
%o f
total
Number
of cases
%o f
total
0 ⁄ 1+ 89 59.4 183 66.5
2+ 32 21.3 40 14.5
3+ 29 19.3 52 19.0
Total 150 100 275 100
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Sigma Plot Version 8 (SPSS Inc., Chicago, IL, USA) and
SPSS Version 15 (SPSS Inc.) were used to perform
statistical analyses including concordance and Cohen’s
j statistics. The Landis and Koch Kappa interpretation
scale was used to evaluate the level of j agreement.
27
The sensitivity and speciﬁcity of both the automated
and manual review were calculated using FISH eval-
uation as the gold standard, where:
Sensitivity ¼
True positives
True positives þ False negatives
ð1Þ
Specificity ¼
True negatives
True negatives þ False positives
ð2Þ
Results
concordance with manual review
The concordance between image analysis evaluation of
HER-2 status and manual review by a Consultant
Pathologist was blindly assessed on a cohort of 275
cases stained with Dako HercepTest
 , Leica Oracle
TM
and Ventana Pathway
 . Statistical analysis established
that there was agreement in the classiﬁcation of 250 of
the 275 cases, representing a concordance of 91%
between the pathology and image analysis reviews
(Table 3). Kappa was evaluated to be 0.81, which
indicates ‘almost perfect’ agreement between manual
review by a pathologist in a reference laboratory and
automated review using image analysis. Table 3 also
reveals that in this study image analysis reported a
lower number of equivocal cases than the manual
pathology review. Indeed, of the 17 cases reclassiﬁed by
image analysis, 15 had been FISH tested and in each of
these cases the gene ampliﬁcation status was concor-
dant with the reclassiﬁed score by image analysis,
suggesting that image analysis would have led to a
signiﬁcant cost saving in this instance. Figure 2 shows
representative images from the system and illustrates
the ability of the HER-2 algorithm to detect regions of
positively and continuously immunoreactive cell mem-
brane.
As expected, analysis of the corresponding cell-line
control material determined that those slides stained
using automated systems exhibited less variance than
those prepared manually. Nonetheless, normalization
to compensate for variance had no impact on the
classiﬁcation of HER-2 by image analysis.
concordance with fish evaluation
A number of cases in the study (n = 136) were also
analysed by FISH, the ‘gold-standard’ method of HER-2
evaluation. The concordance rate between HER-2 gene
ampliﬁcation and IHC review was determined to be
excellent for both image analysis and the pathology
review, demonstrating that image analysis can
robustly and accurately classify HER-2 status (Table 4).
However, it was observed that image analysis review of
the IHC sections attained a slightly higher concordance
rate with FISH than the manual review (95% versus
92%, respectively). Although both methods correctly
classiﬁed 13 FISH+ cases as 3+ IHC cases, quantiﬁca-
tion by image analysis identiﬁed 92 cases with no gene
ampliﬁcation, in comparison with 83 for the pathology
review. This was attributed to improved differentiation
between negative and equivocal cases by image anal-
ysis and suggests that the automated method of review
is more accurate than visual scoring.
Nonetheless, it is evident from Table 4 that signiﬁ-
cant disagreement between IHC classiﬁcation and FISH
ampliﬁcation occurred in six cases, which were subse-
quently re-examined for possible causes of conﬂicting
results. Figure 3 illustrates that IHC staining was
negligible in all of these cases and the pathology and
image analysis reviews agreed that these should be
categorized as negative or 0 ⁄ 1+. However, in each
case gene ampliﬁcation was determined to be positive
by FISH, suggesting these are false-negative IHC cases.
A number of previous studies have reported this
phenomenon in approximately 7% of HER-2 FISH+
results, which would correlate with the ﬁgures deter-
mined here, and the cause is generally attributed to
destruction of the HER-2 epitope or antigen loss during
ﬁxation or processing.
3,28 It was noted that if these
Table 3. Performance of image analysis with clinical samples
assessed on the basis of the American Society of Clinical
Oncology ⁄ College of American Pathologists and UK scoring
guidelines
Image analysis
classiﬁcation
Total 0 ⁄ 1+ 2+ 3+
Manual
classiﬁcation
0 ⁄ 1+ 178 5 0 183
2+ 15 23 2 40
3+ 0 3 49 52
Total 193 31 51 275
Concordance, 90.9%.
j, 0.811.
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review methods would be signiﬁcantly improved, with
HER-2 classiﬁcation by image analysis review achiev-
ing 100% sensitivity and speciﬁcity.
Receiver–operating characteristic curve analysis was
used to compare the accuracy of the manual and image
analysis methods with FISH evaluation as the standard
(Figure 4). The area under the curve value was found
to be 0.93 [95% conﬁdence interval (CI) 0.867, 0.965]
for the manual review with 0.97 (95% CI 0.925,
0.992) obtained by image analysis, conﬁrming the
accuracy of the automated algorithm. Both review
A
B
Figure 2. A, Unprocessed im-
age of breast tissue that has
been immunohistochemically
stained with antibodies probing
for HER-2 protein expression. B,
Areas detected as positive for
continuous membranous
immunoreactivity by image
analysis are highlighted in
green.
Table 4. Concordance between HER-2 gene ampliﬁcation and HER-2 protein expression reviewed by a pathologist and by
image analysis
FISH
IHC
Manual classiﬁcation Image analysis classiﬁcation
Negative
(0 ⁄ 1+)
Positive
(3+)
Equivocal
(2+)
Negative
(0 ⁄ 1+)
Positive
(3+)
Equivocal
(2+)
Positive 7 13 7 6 13 8
Negative 83 1 25 92 0 17
Concordance 92% 93% NA 94% 100% NA
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(P < 0.0001).
comparison with other commercially
available image analysis systems
A number of other image analysis systems are
commercially available for use as decision support
tools in the clinical setting. Nevertheless, Table 5
illustrates that the accuracy in predicting HER-2
status varies considerably across the offerings and a
number of key distinguishing factors exist between the
systems. In comparison with the data submitted by
other systems for Food and Drug Administration
(FDA) approval, this validation study across a larger
cohort of clinical cases has established that Tissue IA
achieved a 5–14% higher correlation with manual
review. Indeed, the 91% concordance rate reported
here is substantially greater than the 70% agreement
detailed by Camp et al.,
2 2003, using the automated
quantitative analysis (AQUA) system. In addition, the
performance of the HER-2 algorithm under trial has
attained high levels of concordance with gene ampli-
ﬁcation status, greater than that reported for the
automated cellular imaging system (ACIS) by Tawﬁk
et al. and Wang et al.
29,30 Furthermore, this system
has been validated to perform with slides stained
using Dako HercepTest
 , Leica Oracle
TM and Ventana
Pathway
  HER-2 antibodies.
The disparity in the accuracy of the image analysis
systems may be attributed to a variety of factors. In the
ﬁrst instance, the HER-2 algorithm reviewed here has
the capacity to identify and eliminate artefactual
staining which may be observed when automated
staining systems are employed or improper use of such
equipment occurs (Figure 5). Without this functional-
ity, true-negative cases may be incorrectly classiﬁed by
image analysis as equivocal due to the high intensity of
immunoreactivity.
Moreover, it is evident from Table 5 that the
distinguishing factor between the image analysis
AB C
DE F
Figure 3. Cases where IA and Manual review agreed on a classiﬁcation of 0 ⁄ 1+ but gene ampliﬁcation was determined to be positive by
ﬂuorescence in situ hybridization. Cases were stained using HER-2 antibodies from: A, Ventana Pathway
 ; B, Ventana Pathway
 ; C, Ventana
Pathway
 ; D, Dako HercepTest
 ; E, Leica Oracle
TM; F, Leica Oracle
TM.
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Figure 4. Receiver–operator curve for the manual and image
analysis review of 136 informative cases (a curve reaching the upper
left corner implies better performance).
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extent of HER-2 protein expression. While all algo-
rithms quantify the intensity of membranous immu-
noreactivity, the algorithm under trial also determines
the continuity of membranous reactivity, the para-
meter that underpins the deﬁnition of positive HER-2
status. Although intensity of reactivity is critical for
distinguishing the 3+ cases, consideration of mem-
brane continuity is essential for clear distinction of
the 0 ⁄ 1+ and the equivocal 2+ categories. Indeed,
Figure 6 demonstrates that although the intensity of
membranous immunoreactivity can appear to be
similar for both groups, the extent of continuity of
that reactivity is undoubtedly a distinguishing factor
that enables correct differentiation of a number of
ambiguous visual IHC scores.
Discussion
High levels of HER-2 protein expression or HER-2 gene
ampliﬁcation are used to identify patients for whom
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Figure 5. A, Artefactual chromogenic staining and B, the ability of
the HER-2 algorithm to identify and exclude these areas from
analysis.
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cancer in the metastatic or adjuvant disease settings.
28
In accordance with the HER-2 testing guidelines, in
most laboratories IHC is carried out ﬁrst with additional
testing accomplished by FISH. However, assignment of
HER-2 grade by assessment of IHC is inherently
subjective and dependent on the skill and experience
of the reviewing pathologist.
31 Thus the standardiza-
tion of diagnosing breast cancer is a very important
task for improving personalized cancer patient care, as
a cancer patient to whom an inappropriate drug is
given will face disease progression during the treatment
time impacting on overall survival rate and increased
costs.
32
The last 10 years have seen enormous advances in
the capabilities of image analysis systems applied to
tissue sections with complex computer algorithms used
to interpret the images.
26 Digital microscopy is increas-
ingly being used to document and analyse tissue
specimens in modern research laboratories and it has
recently been proposed that newly introduced image
analysis technology has a major role to play in the
progress of diagnostic pathology.
12,33 In comparison
with human-based assessment, automated image anal-
ysis offers numerous advantages such as precise,
reproducible, continuous and objective assessment of
protein expression.
17,34 Indeed, image analysis has
been used to evaluate the expression of nuclear
markers such as oestrogen and progesterone receptor;
cytoplasmic markers such as b-catenin; and other
membrane proteins such as E-cadherin.
35,36–38 None-
theless, a major requisite for the acceptance of image
analysis in the clinical laboratory is that it must yield
high concordance with the current gold standard
method. Indeed, although the ASCO ⁄ CAP guidelines
have advocated the use of image analysis for HER-2, a
degree of resistance to its adoption in the clinical
setting has been observed, perhaps due to the low
accuracy and restrictions of the currently available and
approved systems.
The approach detailed in this study has aimed to
address the inherent deﬁciencies in other systems. In
the ﬁrst instance, the algorithm under review measures
the continuity of membranous immunoreactivity as
well as the intensity of reactivity, and has demon-
strated that consideration of both parameters enables
accurate distinction of HER-2 status. Furthermore, this
HER-2 algorithm has been validated to perform with
some of the most prevalent HER-2 antibodies on the
market. Although the HER-2 guidelines for testing do
(i)
A
B
(ii) (iii)
(i) (ii) (iii)
Figure 6. Importance of evaluating circumferential membranous immunoreactivity, which enables differentiation of 1+ and equivocal (2+)
cases by image analysis. A, 1+ in-house control tissue [ﬂuorescence in situ hybridization (FISH) score 1.18]. B, 2+ in-house control tissue (FISH
score 1.97); (i), original image; (ii), regions of issue identiﬁed as immunopositive membrane; (iii), regions of positively and continuously
immunoreactive membrane.
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HercepTest
  and Ventana Pathway
  are recommended
as FDA-approved kits, and the Leica Oracle
TM HER-2
antibody is also frequently employed in laboratories
that have demonstrated concordance with a validated
method.
Our ﬁndings demonstrate that image analysis can
accurately and robustly classify HER-2 status. A
concordance rate of 91% was observed in comparison
with manual review by a pathologist, and the signif-
icant value of image analysis was exempliﬁed by a 4%
reduction in the reporting of equivocal cases. This
represents a decrease in the number of cases requiring
conﬁrmatory FISH testing and thus a potential cost
saving for clinical laboratories. Moreover, the concor-
dance of image analysis with gene ampliﬁcation status
as the standard was observed to be 95%, which
represents better correlation and accuracy with FISH
than the manual interpretation of IHC. The data from
this study are substantially greater than reported by
existing systems in FDA approval documentation and
independently by Camp et al. using the AQUA platform,
or Wang et al. and Tawﬁk et al. using the ACIS
system.
2,29,30 Indeed, in comparison with FISH, the
ACIS system was demonstrated to falsely predict
4–11% of cases as HER-2 ampliﬁed, which could have
a signiﬁcant impact on patient welfare.
29,30 In con-
trast, the platform reviewed here accurately predicted
all HER-2 gene-ampliﬁed cases with a false-positive rate
of 0%.
Although it is generally accepted that the standard
assessment of IHC will remain the manual pathology
review, our ﬁndings suggest that integration of image
analysis into the diagnostic workﬂow could signiﬁ-
cantly enhance the reproducibility of scoring, particu-
larly in those laboratories where there is lack of
experience in interpreting HER-2 staining. However,
aside from providing assistance for interpretation,
image analysis could be utilized as an internal resource
to qualify the quality of IHC, introducing an unprec-
edented level of internal laboratory quality assurance.
Both the ASCO ⁄ CAP and UK guidelines recommend
the use of control material, which should be used
consistently by each laboratory with each run of
tests.
9,11 Although tissue controls are often employed,
this material is frequently difﬁcult to acquire and can
exhibit variation in tumour expression and ﬁxation
that is far from ideal.
39 In contrast, cell lines with
differing but constant levels of HER-2 expression have
been advocated as standard material against which
assay sensitivity can be gauged.
39 Image analysis of cell
line standards could be utilized to assess batch vari-
ability of staining within clinical laboratories, providing
a means to validate the ability of a laboratory to
produce consistently immunostained slides, ﬂagging
batches should intensity of reactivity fall outside of
acceptable limits. This may be of interest to many
external quality assurance providers such as CAP, UK
National External Quality Assessment Service (NE-
QAS), Nordic Immunohistochemical Quality Control
and Royal College of Pathologists of Australasia
(RCPA) Quality Assurance Program (QAP), as it will
enable laboratories to grade their performance against
other facilities using the same standards and antibod-
ies, similar to the annual performance rankings gen-
erated by the RCPA Anatomical Pathology QAP.
Indeed, whilst organizations such as UK NEQAS have
a role to play in ensuring a high standard of quality
assessment, at present UK NEQAS schemes focus
primarily on methodologies rather than the interpre-
tation of results.
40 Nonetheless, Walker et al.
11 docu-
mented that ‘virtual systems are being explored’ and it
is likely that image analysis will play a signiﬁcant role
in the provision of quality assurance schemes in the
future.
Undoubtedly, the recent reports of poor observer
variability regarding the evaluation of HER-2 in the
clinical setting justify the development of software tools
to help standardize interpretation, particularly in
equivocal cases. Based on this study, Tissue IA has
been validated as a consistent scoring tool with
excellent levels of concordance with manual scoring
and FISH, advocating the use of Tissue IA as a decision
support system for pathologists to assist in the diagno-
sis of disease. Further independent studies to demon-
strate the accuracy of the system have been initiated.
Intended use
SlidePath applications are not cleared by the FDA,
Health Canada, or in the EU for diagnostic or clinical
use. All applications are intended solely for use in the
research or educational setting, such as university or
pharmaceutical development. These applications are
described as Research Applications or Research Use
Only.
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